Clinical Trials Sponsored by Zongrui Hospital

Total 101971 results

Jiangsu HengRui Medicine Co., Ltd.

Unknown

The Pharmacokinetics and Pharmacodynamics Study of Single and Multiple Dose of SP2086 in Type 2 Diabetes Patients

Type 2 Diabetes

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

The Drug-drug Interaction of SP2086 and Simvastatin

Type 2 Diabetes

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

The Drug-drug Interaction of SP2086 and Metformin

Type 2 Diabetes
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Phase 1, Randomized, Placebo-controlled, Single & Multiple Dose Escalation Study to Investigate Safety, Pharmacokinetics, and Pharmacodynamics of SHR0534 in Healthy Chinese Volunteers

Healthy
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Study Comparing Remimazolam Tosilate and Propofol for Intravenous General Anaesthesia in Operations

General Anesthesia

China
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Safety and Efficacy Study of Hetrombopag Olamine in Chronic Idiopathic Thrombocytopenic Purpura (ITP) Patients

Chronic Idiopathic Thrombocytopenic Purpura

China
Jiangsu HengRui Medicine Co., Ltd.

Unknown

A Drug Drug Interaciton Study of Imrecoxib and Warfarin in Healthy Volunteers

Knee Osteoarthritis

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Phase I Study of Hetrombopag Olamine in Healthy Adult Volunteers

Healthy

China
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Study Evaluating Pyrotinib/Pyrotinib in Combination With Docetaxel in Patients With HER2+ Advanced Gastric Cancer

HER2 Positive Gastric Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Unknown

The PK/PD, Efficacy, Safety and Tolerability Study of SHR3824 in Type 2 Diabetes Mellitus Patients

Type 2 Diabetes Mellitus

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

The PK/PD Study of Single Dose of SHR3824 in Healthy Volunteers (SHR3824)

Type 2 Diabetes

China
Jiangsu HengRui Medicine Co., Ltd.

Unknown

A Phase Ⅲ Study of Extended-Release Carvedilol Sulfate for the Treatment of Heart Failure

Heart Failure

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

Efficacy and Safety Study of SHR117887 in Combination With Metformin in Patients With Type 2 Diabetes

Type 2 Diabetes
Jiangsu HengRui Medicine Co., Ltd.

Unknown

A Phase II Study of Flumatinib Versus Imatinib to Treat Philadelphia Chromosome Positive Chronic Myelogenous Leukemia

Myelogenous Leukemia, Chronic

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Study Comparing Pegylated rhG-CSF and rhG-CSF as Support to Breast Cancer Patients Receiving Chemotherapy

Breast Cancer | Neutropenia | Febrile Neutropenia

China
Jiangsu HengRui Medicine Co., Ltd.

Terminated

A Phase I Study of Henatinib in Patients With Advanced Solid Malignancies

Advanced Solid Cancer

China
Peking Union Medical College Hospital
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Dalpiciclib With Endocrine Therapy for Advanced Breast Cancer After CDK4/6 Inhibitor Failure (DAWNA-FES)

Advanced Breast Cancer

China
Shanghai Pulmonary Hospital, Shanghai, China
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

The Efficiency of Surgery and Radiotherapy After SHR-1316 (Adebrelimab) and Platinum-containing Doublet Induction Therapy for Limited-stage Small Cell Lung Cancer

Limited Stage Small Cell Lung Cancer

China
Zhigang Li
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

A Trial Of Neoadjuvant Chemotherapy or Radiochemotherapy With Or Without SHR-1210 In Patients With Resectable ESCC.

Locally Advanced Resectable Esophageal Squamous Cell Carcinoma

China
Qilu Hospital of Shandong University
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

Study of PD-1 Antibody and PARP Inhibitor in Extensive Stage Small Cell Lung Cancer

Small Cell Lung Cancer
Peking Union Medical College Hospital
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

Nab-paclitaxel in Combination With Pyrotinib in Postoperative Adjuvant Therapy for HER2-positive Breast Cancer

Early Breast Cancer
Jiangsu HengRui Medicine Co., Ltd.
Peking University Cancer Hospital & Institute

Recruiting

A Phase 1 Study of SHR2554 in Subjects With Relapsed or Refractory Mature Lymphoid Neoplasms

Relapsed or Refractory Mature Lymphoid Neoplasms

China
Shandong Cancer Hospital and Institute
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

A Trial of Conversion Treatment of HAIC Combined With Camrelizumab and Apatinib for Unresected Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
Peking Union Medical College Hospital
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Study of Second-line Treatment With Apatinib in Patients With Advanced Intrahepatic Cholangiocarcinoma

Intrahepatic Cholangiocarcinoma | Second-line Treatment

China
Tianjin Medical University Second Hospital
Jiangsu HengRui Medicine Co., Ltd.

Unknown

The Basket Study of Pyrotinib Maleate for HER2-Postive Solid Tumor

Solid Tumor | HER-2 Gene Amplification | HER2 Gene Mutation | HER-2 Protein Overexpression

China
Jiangsu HengRui Medicine Co., Ltd.
Shanghai Pulmonary Hospital, Shanghai, China

Completed

A Study of Famitinib Plus Docetaxel in Patients With Advanced Non-squamous and Non-Small Cell Lung Cancer (NSCLC)

Non-Small Cell Lung Cancer (NSCLC)

China
Jiangsu HengRui Medicine Co., Ltd.
Peking University Cancer Hospital & Institute

Unknown

A Tolerability and Pharmacokinetics Study of SHR6390 in Advanced Melanoma Patients

Melanoma

China
Peking University Cancer Hospital & Institute
Jiangsu HengRui Medicine Co., Ltd.

Unknown

A Study of Second-line Treatment With Apatinib After TACE in Advanced Hepatocellular Carcinoma Patients

Hepatocellular Carcinoma

China
Peking Union Medical College Hospital
Jiangsu HengRui Medicine Co., Ltd.

Unknown

An Open Label, Prospective, Multicentre, Non-interventional Study of Apatinib for Chemotherapy-Refractory Advanced Metastatic Gastric Cancer (AHEAD-G202)

Metastatic Gastric Cancer

China
Guangdong Hengrui Pharmaceutical Co., Ltd

Not yet recruiting

A Study to Evaluate the Long-term Safety, Pharmacodynamics and Efficacy of SHR-1703 in Eosinophilic Asthma Patients

Eosinophilic Asthma Patients
Shanghai Hengrui Pharmaceutical Co., Ltd.

Not yet recruiting

Phase Ib/II Study of HRS2398 in Combination With Adebrelimab in Patients With Advanced Solid Tumors

Advanced Solid Tumors

China
Shanghai Hengrui Pharmaceutical Co., Ltd.

Not yet recruiting

The Trial of SHR6508 in Secondary Hyperparathyroidism

Secondary Hyperparathyroidism

China
Shanghai Hengrui Pharmaceutical Co., Ltd.

Not yet recruiting

A Trial of SHR-A2102 With or Without Antitumor Therapy in Advanced Solid Tumors

Advanced Solid Tumors
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Study to Evaluate the Mass Balance of [14C]SHR7280 in Healthy Adult Volunteers

Assisted Reproduction

China
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

A Phase II Study of SHR2554 in Patients With Relapsed or Refractory Follicular Lymphoma

Follicular Lymphoma

China
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

A Study of Bupivacaine Liposome Injection in Local Analgesia of Pediatric Patients

Local Analgesia Via Infiltration

China
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

Randomized, Double-blind, Placebo-controlled Study of RSS0393 Ointment in Healthy and Psoriatic Subjects

Healthy | Psoriatic Subjects
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

A Trial of HHPG-19K Injection and Auto-HHPG-19K Injection in Prevention of Chemotherapy-related Moderate to Severe Neutropenia of Patients With Nonmyeloid Malignancies

Patients With Nonmyeloid Malignancies Receiving Antineoplastic Therapy Based on Chemotherapy Regimens at Moderate to High Febrile Neutropenia (FN) Risk

China
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

A Study of Remimazolam Tosilate for Sedation in the ICU

Sedation in the ICU
Shanghai Hengrui Pharmaceutical Co., Ltd.

Recruiting

Safety and Pharmacodynamics of SHR-1707 in Alzheimer's Disease Patients

Alzheimer's Disease

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Study of SHR2554 With Chemotherapy in Treatment-naïve Patients With Peripheral T-cell Lymphoma

Peripheral T-cell Lymphoma

China
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

A Trial of Intravenous HRS-8427 in the Treatment of Adults With Complicate Urinary Tract Infection, Including Acute Pyelonephritis

Patients With Complicated Urinary Tract Infection(cUTI), Including Acute Pyelonephritis(AP)
Guangdong Hengrui Pharmaceutical Co., Ltd

Recruiting

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SHR-3032 in Healthy Subjects

Prevention of Graft Rejection After Organ Transplantation

China
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

Phase I Clinical Study of HRS-9815 for PET/CT Imaging in Patients With Prostate Cancer

Prostate Cancer
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

A Phase III Study of SHR-A1811 Injection With or Without Pertuzumab in HER2-Positive Recurrent or Metastatic Breast Cancer

HER2-PositiveRecurrent or Metastatic Breast Cancer
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Study to Assess the Efficacy and Safety of HRG2005 Inhalation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Trial of SHR-A1811 Combined With Other Antitumor Therapies in Advanced Solid Tumors.

HER2-expressing Advanced Solid Tumors

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Phase 1 Trial to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SHR-3167 Single Injection in Healthy Subjects and Patients With Type 2 Diabetes

T2DM

China
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

Phase I Study of HRS-7053 Injection in the Treatment of Patients With Advanced Malignancies

Advanced Malignant Cancer
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Pharmacokinetic/Pharmacokinetic and Safety Studies of SHR4640 in Subjects With Moderate Renal Insufficiency and Healthy Subjects

Hyperuricemia

China

3

Subscribe